inhaled/swallowed budesonide + viscous/swallowed budesonide
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Eosinophilic Esophagitis
Conditions
Eosinophilic Esophagitis
Trial Timeline
Oct 1, 2009 → Nov 1, 2011
NCT ID
NCT00961233About inhaled/swallowed budesonide + viscous/swallowed budesonide
inhaled/swallowed budesonide + viscous/swallowed budesonide is a pre-clinical stage product being developed by AstraZeneca for Eosinophilic Esophagitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00961233. Target conditions include Eosinophilic Esophagitis.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00961233 | Pre-clinical | Completed |
Competing Products
20 competing products in Eosinophilic Esophagitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KHK4563 + KHK4563 + KHK4563 + Placebo | Kyowa Kirin | Phase 2 | 52 |
| benralizumab + benralizumab + Placebo | Kyowa Kirin | Phase 2 | 52 |
| SHR-1703 + SHR-1703 Placebo | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| NS-229 + Placebo | Nippon Shinyaku | Phase 2 | 52 |
| Esomeprazole + Budesonide | AstraZeneca | Phase 2/3 | 65 |
| Tezepelumab + Tezepelumab | AstraZeneca | Phase 3 | 77 |
| Benralizumab | AstraZeneca | Approved | 85 |
| Cohort | AstraZeneca | Pre-clinical | 23 |
| Benralizumab + Matching placebo | AstraZeneca | Phase 3 | 77 |
| Benralizumab | AstraZeneca | Phase 3 | 77 |
| Benralizumab + Mepolizumab + Placebo to Mepolizumab + Placebo to Benralizumab | AstraZeneca | Phase 3 | 77 |
| Benralizumab Prefilled Syringe | AstraZeneca | Approved | 85 |
| benralizumab | AstraZeneca | Pre-clinical | 23 |
| Benralizumab + Placebo | AstraZeneca | Phase 3 | 77 |
| Benralizumab | AstraZeneca | Phase 3 | 77 |
| Benralizumab + Placebo | AstraZeneca | Phase 3 | 77 |
| Tezepelumab + Placebo | AstraZeneca | Phase 2 | 52 |
| Benralizumab + Placebo | AstraZeneca | Phase 2/3 | 65 |
| Benralizumab + 129 Xenon | AstraZeneca | Pre-clinical | 23 |
| Benralizumab + Placebo | AstraZeneca | Phase 3 | 77 |